Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes Journal Article


Authors: Weber, S. M.; Jarnagin, W. R.; Klimstra, D.; DeMatteo, R. P.; Fong, Y.; Blumgart, L. H.
Article Title: Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes
Abstract: BACKGROUND: Intrahepatic cholangiocarcinoma (IHC) is a rare primary hepatic tumor of bile duct origin for which resection is the most effective treatment. But resectability, outcomes after resection, and recurrence patterns have not been well described. STUDY DESIGN: Patients with IHC were identified from a prospective database. Demographic data, tumor characteristics, and outcomes were analyzed. RESULTS: From March 1992 to September 2000, 53 patients with hepatic tumors underwent exploration and were found to have pure IHC on pathologic analysis. Patients with mixed hepatocellular and cholangiocarcinoma tumors were excluded. At exploration, 20 patients were unresectable for an overall resectability rate of 62% (33 of 53). Median survival for patients submitted to resection was 37.4 months versus 11.6 months for patients undergoing biopsy only (p = 0.006; median followup for surviving patients, 15.6 months). Actuarial 3-year survival was 55% versus 21%, respectively. Factors predictive of poor survival after resection included vascular invasion (p = 0.0007), histologically positive margin (p = 0.009), or multiple tumors (p = 0.003). After resection, 20 of 33 patients (61%) recurred at a median of 12.4 months. Sites of recurrence included the liver (14), retroperitoneal or hilar nodes (4), lung (4), and bone (2). The median disease-free survival was 19.4 months, with a 3-year disease-free survival rate of 22%. Factors predictive of recurrence were multiple tumors (p = 0.0002), tumor size (p = 0.001), and vascular invasion (p = 0.01). CONCLUSIONS: About two-thirds of patients who appeared resectable on preoperative imaging were amenable to curative resection at the time of operation. Although complete resection improved survival, recurrence was common. The majority of recurrences were local or regional, which may help guide future adjuvant therapy strategies. © 2001 by the American College of Surgeons.
Keywords: adult; cancer survival; treatment outcome; aged; aged, 80 and over; disease-free survival; middle aged; survival analysis; survival rate; major clinical study; cancer recurrence; liver neoplasms; adjuvant therapy; preoperative evaluation; prospective studies; metastasis; neoplasm recurrence, local; proportional hazards models; risk factors; diagnostic imaging; chi-square distribution; hepatectomy; bile duct carcinoma; cholangiocarcinoma; liver biopsy; actuarial analysis; humans; prognosis; human; male; female; priority journal; article
Journal Title: Journal of the American College of Surgeons
Volume: 193
Issue: 4
ISSN: 1072-7515
Publisher: Elsevier Science, Inc.  
Date Published: 2001-10-01
Start Page: 384
End Page: 391
Language: English
DOI: 10.1016/s1072-7515(01)01016-x
PUBMED: 11584966
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leslie H Blumgart
    352 Blumgart
  2. Ronald P DeMatteo
    637 DeMatteo
  3. Sharon M Weber
    12 Weber
  4. David S Klimstra
    978 Klimstra
  5. William R Jarnagin
    903 Jarnagin
  6. Yuman Fong
    775 Fong